Startups channel feed

New York gene ther­a­py start­up Neu­ro­gene eyes $200M from Ne­oleukin Nas­daq swap

Last year
Deals
Cell/Gene Tx

Turn­stone charts $75M IPO for TIL cell ther­a­pies in drum­roll of biotech IPOs this month

Last year
Financing

West­lake at­tracts an­oth­er $450M to fu­el star­tups in LA's nascent biotech scene

Last year
Financing

Fre­quen­cy to hand Nas­daq spot to Ko­r­ro Bio as At­las-found­ed RNA edit­ing start­up nabs $117M

Last year
Deals

Up­dat­ed: In Fri­day IPO dou­ble­head­er, Apogee and Sagimet help crack open a stuck win­dow on Wall Street

Last year
Financing

Roche li­cens­es KSQ's PhI can­cer small mol­e­cule, with cash in­fu­sion to help bankroll biotech's TIL cell ther­a­pies

Last year
Deals

Causaly, an AI start­up help­ing with pre­clin­i­cal dis­cov­ery, nabs $60M from VCs and for­mer J&J chief Alex Gorsky

Last year
Financing
AI

Bio­Gen­er­a­tion Ven­tures clos­es $167M fund to hatch Eu­ro­pean star­tups with back­ing from Eli Lil­ly, No­vo, BMS

Last year
Financing

Ten­point Ther­a­peu­tics launch­es with $70M to re­store vi­sion with stem cell ther­a­pies and ‘re­pro­gram­ming’ med­i­cines

Last year
Financing
Cell/Gene Tx

BAKX Ther­a­peu­tics to shut down af­ter ‘sci­en­tif­ic chal­lenges’ and fi­nanc­ing dol­drums

Last year
People

Ex­clu­sive: Brig­gs Mor­rison's Cross­bow Ther­a­peu­tics nabs $80M from MPM, Pfiz­er Ven­tures, Lil­ly in hunt for bet­ter can­cer drugs

Last year
Financing

Septer­na’s $150M in­fu­sion will help prove whether it’s got the right pill for hy­poparathy­roidism

Last year
Financing

BeiGene fur­ther in­vests in AD­Cs with sol­id tu­mor part­ner Du­al­i­ty­Bio, a BioN­Tech col­lab­o­ra­tor

Last year
Deals
China

Apogee and Sagimet’s IPO plans come in­to view, with tar­get­ed rais­es of $228M and $66M

Last year
Financing

Gal­va­nize turns to lay­offs less than a year af­ter merg­ing three Ap­ple Tree com­pa­nies, rais­ing $100M

Last year
People

Gene ther­a­py biotech Cap­si­da lays off work­ers af­ter ex­pand­ing Ab­b­Vie pact, adding Lil­ly col­lab

Last year
People
Cell/Gene Tx

Sagimet Bio­sciences files again for an IPO af­ter re­leas­ing NASH da­ta

Last year
Financing

Elu­ci­da On­col­o­gy nabs more funds for its take on AD­Cs, sees po­ten­tial in ra­dio­ther­a­py part­ner­ship

Last year
Financing

Apogee files to go pub­lic, un­veil­ing plans to make a play for Dupix­en­t's turf

Last year
Financing

Ae­glea Bio­Ther­a­peu­tics ac­quires start­up Spyre in bid to go af­ter Mer­ck’s Prometheus, Roivant’s Tela­vant

Last year
Financing
Deals

Tour­ma­line Bio re­verse merges in­to Ta­laris and rais­es funds to tar­get thy­roid eye dis­ease and phar­ma ri­vals

Last year
Financing
Deals

Tag­works lands $65M for its take on No­bel-win­ning click chem­istry in bid to ex­pand ADC, ra­dio­phar­ma po­ten­tial

Last year
Financing

Por­tal In­no­va­tions to call Hous­ton its third home, with CAR-T start­up March Bio­sciences al­ready in the port­fo­lio

Last year
Financing
Cell/Gene Tx

Art­bio emerges with $23M to make ra­di­oli­gand ther­a­pies for prostate can­cer, with field still in 'ear­ly days'

Last year
Financing
First page Previous page 27282930313233 Next page Last page
A service from the Financial Times